Holen Sie sich die Stockscreener-App
0.00
100.00%
-1.35
Handel nachbörslich:
1.37
1.37
+
Chromocell Therapeutics Corp Aktie (CHRO) Neueste Nachrichten
Channel Therapeutics Faces Financial Uncertainty as Auditors Issue Going Concern Warning - Stock Titan
Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics - marketscreener.com
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings - Benzinga
Ligand subsidiaries, Chromocell Therapeutics to merge - TipRanks
Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics - marketscreener.com
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - GlobeNewswire Inc.
Channel Therapeutics Corporation announced that it has received $0.25 million in funding -February 24, 2025 - Marketscreener.com
Channel Therapeutics secures $325,000 promissory note By Investing.com - Investing.com Australia
Channel Therapeutics secures $325,000 promissory note - Investing.com India
New Biotech Stocks at Investorideas.com - Investorideas.com newswire
Wall Street-Heavily Traded - WDRB
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Channel Therapeutics Advances Novel Pain Treatment Strategy with NaV1.7 Inhibitor Pipeline - Stock Titan
Channel Therapeutics' Pain Treatment Breakthrough: Novel Nerve Block Outperforms Standard Care in Key Trial - StockTitan
Chromocell changes name to Channel Therapeutics, provides program updates - Nasdaq
Channel Therapeutics finalizes corporate restructuring - Investing.com
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - The Manila Times
Chromocell to Present at Upcoming Fall Investor Conferences - StockTitan
Chromocell Therapeutics amends stock repurchase plan - TradingPedia
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - GlobeNewswire
Another Delaware Publicly Traded Company Proposes A Nevada Move | Allen Matkins - JD Supra
Chromocell to Participate in Life Sciences Investor Forum September 19th - Yahoo Finance
CDMO Benuvia Appoints Terry Novak As New CEO - Pharmaceutical Online
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet - CNBC
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session - TradingView
Chromocell Issues Letter to Stockholders from Chief Executive Officer - StockTitan
Chutes & Ladders—Bayer undergoes leadership shake-up - Fierce Biotech
Are there bright times for biotech IPOs ahead? - European Biotechnology Magazine
Sidoti Events, LLC's Virtual March Small-Cap Conference - Yahoo Finance
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million - Stock Titan
CHRO Stock Price and Chart — AMEX:CHRO - TradingView
CHROChannel Therapeutics Corporation Latest Stock News & Market Updates - StockTitan
CHRO IPO NewsPain relief biotech Chromocell Therapeutics sets terms for $9 million IPO - renaissancecapital.com
Biotech Venture in the UAE Validated by IPO in the U.S. - PR Newswire
Tina Garyantes – Feliciano Center For Entrepreneurship And Innovation - Montclair State University
Stocks Telegraph - Stocks Telegraph
Nestlé and Chromocell Extend Collaboration to Find Alternatives to Salt - Food Manufacturing
Improving the Reliability and Utility of Streptozotocin‐Induced Rat Diabetic Model - Wiley Online Library
Chromocell Announces Initiation of Multiple Ascending Doses Portion of Phase 1 Clinical Trial - PR Newswire
Chromocell and Astellas Announce FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN - PR Newswire
News from Central Jersey's pharma, biotech industries - Central New Jersey News
Astellas, Chromocell Launch Up-to-$515M+ Pain Drugs Collaboration - Genetic Engineering and Biotechnology News
1.45%
0.86%
Kapitalisierung:
|
Volumen (24h):